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Abstract: A synthetic sequence has been developed for the preparation of 9,10- 
di-O-diacetyl-4-desmethylene-4β-(3-butenyl)-4α-hydroxy-5-O-mesyltaxicin I- 
-1,2-carbonate 3, an intermediate in an attempted synthesis of a cyclobutane 
paclitaxel analogue. A series of reactions of 3 were investigated, including the 
protection of the sterically hindered C-4α-hydroxy group and the oxidative 
cleavage of the terminal double bond. Cyclization of 13 to the cyclobutane-
containing intermediate failed due to the unexpected instability of the dime-
thylsilane protecting group under basic conditions.  
Keywords: taxoids; taxanes antitumor agents; radical allylation; silyl protecting 
groups. 
INTRODUCTION 
Over the past 25 years, structure–activity relationships (SAR) studies on the 
antitumor agent paclitaxel have been thoroughly conducted, identifying the major 
sites involved in its microtubules stabilizing activity.1 Among these numerous 
studies, considerable research efforts were directed toward the understanding of 
the role of the oxetane D-ring in the cytotoxic activity of paclitaxel.2 The contri-
bution of this ring to the biological activity of paclitaxel is not clear and two 
hypotheses have been proposed as explanations.2d,f The inflexible oxetane ring 
may force the molecule to adopt a biologically active conformation through its 
rigidifying effect on the taxane skeleton,2e,k or the oxetane oxygen atom might 
be involved in the stabilizing dipolar or hydrogen bonding interactions with the 
tubulin protein.2b,c,h 
In the course of our studies on D-modified 7-deoxypaclitaxel analogues,2l,n,3 
we wished to synthesize analogue 1 in which the oxetane ring would be replaced 
by cyclobutane, according to the retrosynthetic plan presented in Scheme 1. Ana-
logue 1, as compared with paclitaxel, possesses a conformationally rigid four-
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membered D-ring without the electronegative oxygen atom in it. This modifica-
tion should allow us to determine whether the oxetane ring exerts its influence to 
the biological activity of taxoids through conformational or electronic effects. 
 
Scheme 1. Retrosynthetic analysis of cyclobutane paclitaxel analogue 1. 
RESULTS AND DISCUSSION 
As the starting material for the preparation of analogue 1, we chose triol 4, 
one of the intermediates in our synthesis of 7-deoxy-C,D-seco-paclitaxel from 
taxine B (Scheme 2).2l,n Mesylation of the free C-20 and C-5 hydroxyl groups af-
orded 5 in good yield. Exposure of 5 to the action of the Hunig’s base in reflux-
ing toluene furnished epoxymesylate 6, which was converted to bromohydrin 7 
by Lewis acid induced nucleophilic opening of the 4(20)-epoxide. Finally, alco-
hol 3 was obtained by a free radical allylation of compound 7 with allyltributyl-
tin, using AIBN as initiator. This protocol for elongation of the C-4β alkyl chain 
had already been successfully applied in our synthesis of the C,D-spirolactone 
analogue of paclitaxel.2o It is interesting to note that radical allylation of com-
 
Scheme 2. Conversion of triol 4 into the DMS-protected alcohol 10. Reagents, conditions and 
yields: a) MsCl, pyridine, rt, 72 h, 70 %; b) DIPEA, PhCH3, 120 °C, 3 h, 87 %; c) Bu4NBr, 
BF3·OEt2, DCM, rt, 15 min, 84 %; d) allyltributyltin, AIBN, PhH, reflux, 3 h, 3 57 % and 8 
15 %; e) DMSCl, imidazole, DMF, 55 °C, 67 % f) MOMCl, NaI, DIPEA, DME, 86 °C, 26 %. 
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pound 7 requires the use of a large amount of the initiator: when the standard 
reaction conditions (catalytic quantities of AIBN) were applied, only the starting 
material was isolated. However, performing the reaction with 3–4.5 equivalents 
of the initiator allowed us to obtain alcohol 3 in 57 % yield. Use of such a large 
amount of the initiator resulted in the formation of side product 8 (15 % yield), 
probably by reduction of the intermediary C-20 radical with AIBN. 
All attempts to protect the tertiary hydroxyl group in 8 were unsuccessful, 
undoubtedly a direct result of a considerable steric hindrance. For example, treat-
ment of 8 with TMSCl/imidazole in DMF, NaH/MeI in THF or lithium hexame-
thyldisilazide/methyl chloroformate in THF2c led only to the recovery of starting 
material. Attempted acetylation under forcing conditions with excess Ac2O/  
/DMAP2i in toluene at 60 °C also failed to provide the desired product. Interest-
ingly, application of reaction conditions for the protection of tertiary alcohol as a 
methoxymethyl (MOM) ether (MOMCl, NaI, DMF, N,N-diisopropylethylamine, 
reflux)4 caused only the elimination of C-5 mesylate and the formation of com-
pound 9. Finally, we found that treatment of 3 with chlorodimethylsilane and 
imidazole in DMF at 55 °C afforded the dimethylsilane (DMS) protected com-
pound 10 in 67 % yield. Chlorodimethylsilane is a small and reactive reagent and 
it has already been successively used as a “specific” protecting group for the C-1 
tertiary hydroxyl group of taxoids.5 
We next turned our attention to the oxidative cleavage of the terminal double 
bond in the silyl ether 10 (Scheme 3). Some preliminary experiments indicated 
that during the reaction of 10 with a mixture of osmium tetraoxide and sodium 
periodate in THF/water, oxidation of the DMS protecting group also occurred, 
resulting in the formation of 11. The 1H-NMR spectrum exhibited two singlets 
for the methyls from the DMS group (instead of two doublets) and the absence of 
the DMS hydrogen atom. The desired transformation could be accomplished by 
ozonolysis: exposure of 10 to the action of ozone, followed by treatment with 
dimethyl sulfide to furnish aldehyde 12. Oxidation of aldehyde 12 with oxone6 in 
DMF and subsequent esterification of the carboxylic acid afforded compound 13 
in 61 % yield (over two steps). The crucial ring-closure step in the synthesis – 
formation of the cyclobutane ring – was planned to be effected by the treatment 
of methyl ester 13 with potassium hexamethyldisilazide in THF at low tempera-
ture. However, these conditions proved conducive to the loss of the DMS pro-
tecting group and cyclization of thus obtained C-4 alcohol into lactone 14. The 
outcome of this reaction was quite unexpected bearing in mind previous work 
from Chen,5b in which the DMS protecting group was unaffected under similar 
reaction conditions. Alternatively, lactone 14 could also be obtained directly 
from alcohol 3 by the action of OsO4 and NaIO4 followed by oxidation of the 
intermediary hemiacetal with Jones reagent.2o Finally, according to the previ-
ously observed elimination of the C-5 mesylate in alcohol 3, we tried to form a 
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Δ5,6 double bond in 14. The presence of a 5,6-double bond in the analogue with a 
C,D-spirolactone moiety could induce a conformational change of the C-ring 
which positiones the essential C-2, C-13 and C-4 ester groups in the appropriate 
spatial orientation for the improved biological activity of this type of taxoids.1b,c 
We have previously shown that the C,D-spirolactone paclitaxel analogue was the 
first D-ring-modified analogue to show significant cytotoxicity, as a result of a 
different mechanism of action in comparison with paclitaxel, involving mTOR 
inhibition-dependent autophagy instead of G2/M cell cycle arrest-dependent 
apoptosis.2o Therefore, elimination of C-5 mesylate in 14 was attempted with 
several bases (N,N-diisopropylethylamine, DBU): unfortunately, these experi-
ments led only to the recovery of starting material. Treatment of 14 with a nuc-
leophile, such as the thiophenoxide anion, resulted in the formation of a complex 
mixture of polar products. The difference in reactivity between compounds 3 and 
14 suggests that neighboring free C-4 hydroxyl group in 3 activates the C-5 me-
sylate toward elimination by intramolecular hydrogen bonding. 
 
Scheme 3. Preparation of intermediate 13 and conversion of 3 and 13 into 14. Reagents and 
conditions: a) OsO4, NaIO4, THF, H2O, rt, 3 h, 42 %; b) O3, DCM, –80 °C, then Me2S, 18 h, 
58 %; c) oxone, DMF, rt, 1 h, then CH2N2, THF, 0 °C, 1 h, 61 %; d) KHMDS, THF, 
–78 °C, 30 min, 77 %; e) OsO4, NaIO4, THF, H2O, rt, 1 h; 
f) Jones reagent, acetone, 0 °C, 49 % from 3. 
EXPERIMENTAL 
General experimental. All chromatographic separations7 were performed on silica, 10-
18, 60A, ICN Biomedicals. Standard techniques were used for the purification of the reagents 
and solvents.8 The NMR spectra were recorded on a Varian Gemini 200 (1H-NMR at 200 
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MHz, 13C-NMR at 50 MHz, for samples in deuterated chloroform), and on a Bruker Avance 
III 500 (1H-NMR at 500 MHz, 13C-NMR at 125 MHz). The chemical shifts are expressed in 
ppm (δ) using tetramethylsilane as an internal standard and the coupling constants (J) are in 
Hz. The IR spectra were recorded on a Nicolet 6700 FT instrument and are expressed in cm-1. 
The mass spectra were obtained on Agilent Technologies 6210 TOF LC/MS instrument (LC: 
series 1200). 
Compound 5. To a solution of 4 (65 mg; 0.13 mmol) in pyridine (4 mL) at 0° C was 
added mesyl chloride (222 mg; 1.95 mmol; 15 eq). The reaction mixture was stirred at 0° C 
for 15 min and then allowed to warm to rt. After 24 h, a second batch of mesyl chloride (222 
mg) was added and stirring of the reaction mixture was continued for 24 h. The reaction 
mixture was diluted with CH2Cl2 and the resulting solution was washed successively with ice-
cold 2.5% HCl, aq. NaHCO3 and water and dried over anh. MgSO4. After removal of the 
solvent under reduced pressure, the residue was purified by dry flash chromatography (eluent: 
benzene/ethyl acetate = 1/1) to give 5 (60 mg, 70%) as a colorless film. IR (film, cm-1): 3489, 
2998, 2937, 1812, 1750, 1686, 1412, 1354, 1237, 1175, 1026; 1H-NMR (200 MHz; CDCl3, δ /  
/ ppm): 6.04 (1H, d, J = 10.3 Hz), 5.63 (1H, d, J = 10.0 Hz), 4.92 (1H, bs), 4.89 (1H, d, J = 3.7 
Hz), 4.62 (1H, d, J = 11.4 Hz), 4.48 (1H, d, J = 11.4 Hz), 3.99 (1H, s), 3.90 (1H, d, J = 19.4 
Hz), 3.15 (3H, s), 3.00 (3H, s), 2.91 (1H, d, J = 3.67 Hz), 2.86 (1H, d, J = 19.1 Hz), 2.26 (3H, 
s), 2.11 (3H, s), 2.10–1.60 (4H, m), 2.05 (3H, s), 1.67 (3H, s), 1.34 (3H, s), 0.97 (3H, s); 13C- 
-NMR (50 MHz, CDCl3, δ / ppm): 197.04 (C), 170.17 (C), 169.19 (C), 152.41 (C), 149.83 
(C), 143.35 (C), 88.90 (C), 79.58 (CH), 79.13 (CH), 75.00 (CH), 73.70 (C), 72.58 (CH), 68.52 
(CH2), 43.74 (CH), 43.24 (C), 41.44 (C), 40.80 (CH2), 38.73 (CH3), 37.27 (CH3), 32.68 (CH3), 
24.78 (2×CH2), 20.59 (CH3), 20.50 (CH3), 19.92 (CH3), 18.95 (CH3), 13.68 (CH3); HRMS 
(ESI-TOF high acc) calcd. for C27H39O15S2 (MH+) 667.1725, found 667.1727. 
Compound 6. A solution of 5 (134 mg; 0.20 mmol) and DIPEA (181 mg; 1.4 mmol; 7 
eq) in anhydrous toluene (21 mL) was heated to reflux with stirring for 3 h. The solvent was 
removed under reduced pressure and the residue was purified by dry flash chromatography 
(eluent: benzene/ethyl acetate = 1/1) to give compound 6 (100 mg; 87%) as a colorless film. 
IR (film, cm-1): 2994, 2939, 1815, 1746, 1688, 1435, 1371, 1236, 1175, 1036; 1H-NMR (200 
MHz; CDCl3, δ / ppm): 6.09 (1H, d, J = 10.3 Hz), 5.72 (1H, d, J = 10.3 Hz), 4.75 (1H, d, J = 
= 4.4 Hz), 4.20 (1H, bs), 3.45 (1H, d, J = 4.0 Hz), 3.23 (1H, d, J = 4.4 Hz), 3.11 (1H, d, J = 
= 19.4 Hz), 3.04 (3H, s), 2.94 (1H, d, J = 19.4 Hz), 2.73 (1H, d, J = 4.0 Hz), 2.31 (3H, s), 2.13 
(3H, s), 2.13–1.60 (4H, m), 2.05 (3H, s), 1.63 (3H, s), 1.33 (3H, s), 1.08 (3H, s); 13C-NMR (50 
MHz, CDCl3, δ / ppm): 196.20 (C), 170.02 (C), 169.33 (C), 152.12 (C), 150.10 (C), 143.98 
(C), 87.78 (C), 85.54 (CH), 77.96 (CH), 74.85 (CH), 72.43 (CH), 59.36 (C), 51.76 (CH2), 
44.30 (C), 41.44 (C), 40.88 (CH2), 38.69 (CH3), 37.93 (CH), 32.59 (CH3), 26.98 (CH2), 25.33 
(CH2), 20.67 (CH3), 20.50 (CH3), 19.92 (CH3), 17.52 (CH3), 14.29 (CH3); HRMS (ESI-TOF 
high acc) calcd. for C26H35O12S (MH+) 571.1844, found 571.1834.  
Compound 7. To a solution of 6 (280 mg, 0.49 mmol) and Bu4NBr (630 mg, 1.96 mmol, 
4 eq) in CH2Cl2 (25 mL) was added BF3•Et2O (139 mg, 0.98 mmol, 2 eq) dropwise at rt under 
an argon atmosphere. The reaction mixture was stirred for 15 min and diluted with CH2Cl2, 
washed successively with water and brine, dried over anhydrous MgSO4 and concentrated 
under reduced pressure. Purification by dry-flash chromatography (eluent:benzene/ethyl ace-
tate = 7/3) gave compound 7 (255 mg, 80%) as white powder. m.p. 256 °C with decompo-
sition. IR (film, cm-1): 3467, 2928, 1812, 1750, 1686, 1360, 1233, 1173, 1027; 1H-NMR (200 
MHz; CDCl3, δ / ppm): 6.04 (1H, d, J = 10.2 Hz), 5.63 (1H, d, J = 10.2 Hz), 5.03 (1H, bs), 
4.83 (1H, d, J = 4.7 Hz), 4.16 (1H, d, J = 11.7 Hz), 3.87 (1H, d, J = 19.3 Hz), 3.79 (1H, d, J = 
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= 12.0 Hz), 3.11 ( 1H, s), 3.07 (1H, d, J = 4.4 Hz), 3.00 (3H, s), 2.86 (1H, d, J = 19.3 Hz), 
2.27 (3H, s), 2.12 (3H, s), 2.12–1.60 (4H, m), 2.06 (3H, s), 1.67 (3H, s), 1.34 (3H, s), 1.02 
(3H, s); 13C-NMR (50 MHz, CDCl3, δ / ppm): 196.95 (C), 170.29 (C), 169.20 (C), 152.12 (C), 
149.59 (C), 143.49 (C), 88.82 (C), 80.52 (CH), 79.33 (CH), 75.09 (CH), 73.27 (C), 72.54 
(CH), 43.83 (CH), 43.44 (C), 41.48 (C), 40.84 (CH2), 38.67 (CH3), 38.33 (CH2), 32.77 (CH3), 
25.00 (2×CH2), 20.68 (CH3), 20.63 (CH3), 20.05 (CH3), 19.43 (CH3), 13.78 (CH3); HRMS 
(ESI-TOF high acc) calcd. for C26H36BrO12S (MH+) 651.1105, found 651.1094. 
Compound 3. A deaerated solution of 7 (220 mg, 0.34 mmol), allyltributyltin (1.68 g, 
5.08 mmol, 15 eq) and AIBN (83 mg, 0.51 mmol, 1.5 eq) in benzene (44 mL) was stirred at 
80 °C under an argon atmosphere. After 1 h, AIBN (83 mg) was added and stirring and 
heating of the reaction mixture were continued for 1 h. After removal of the solvent under 
reduced pressure, the residue was purified by dry-flash chromatography (eluent: benzene/ethyl 
acetate = 8/2) to give compound 3 (120 mg, 57%) and compound 8 (29 mg, 15%) as a color-
less films. Compound 3: IR (film, cm-1): 3542, 3439, 2946, 1812, 1750, 1684, 1349, 1234, 
1172, 1034; 1H-NMR (500 MHz, CDCl3, δ / ppm): 6.04 (1H, d, J = 10.5 Hz, H-10), 5.86–5.78 
(1H, m, H-22), 5.62 (1H, d, J = 10.5 Hz, H-9), 5.11 (1H, broad dd, J = 1.0 and 17.0 Hz, H-23), 
5.06 (1H, dd, J = 1.0 and 10.0 Hz, H-23), 4.88 (1H, d, J = 4.5 Hz, H-2), 4.79 (1H, bs, H-5), 
3.79 (1H, d, J = = 19.0 Hz, H-14), 2.97 (3H, s, Ms), 2.90 (1H, s, OH), 2.84 (1H, d, J = 19.0 
Hz, H-14), 2.78 (1H, d, J = 4.5 Hz, H-3), 2.32–2.23 (1H, m, H-21), 2.26 (3H, s, H-18), 2.23– 
–2.13 (2H, m, H-20 and H-21), 2.11 (3H, s, Ac), 2.05 (3H, s, Ac), 2.06–1.98 (1H, m, H-6), 
1.91–1.85 (1H, m, H-6), 1.78–1.68 (3H, m, H-20 and 2×H-7), 1.67 (3H, s, H-16 or H-17), 1.33 
(3H, s, H-16 or H-17), 1.03 (3H, s, H-19); 13C-NMR (125 MHz, CDCl3, δ / ppm): 197.18 (C, 
C-13), 170.45 (C, Ac), 169.38 (C, Ac), 152.53 (C, CO), 149.71 (C, C-11), 143.45 (C, C-12), 
137.66 (CH, C-22), 116.60 (CH2, C-23), 89.38 (C, C-1), 81.74 (CH, C-5), 80.41 (CH, C-2), 
75.70 (C, C-4), 75.60 (CH, C-9), 72.88 (CH, C-10), 45.23 (CH, C-3), 43.82 (C, C-8), 41.50 
(C, C-15), 41.16 (CH2, C-14), 38.82 (CH3, Ms), 35.34 (CH2, C-20), 33.02 (CH3, C-16 or 
C-17), 28.24 (CH2, C-21), 25.52 (CH2, C-6), 25.44 (CH2, C-7), 20.90 (CH3, Ac), 20.81 (CH3, 
Ac), 20.27 (CH3, C-16 or C-17), 19.18 (CH3, C-19), 13.99 (CH3, C-18). HRMS (ESI-TOF high 
acc) calcd. for C29H41O12S (MH+): 613.2313, found: 613.2318. Compound 8: IR (film, cm-1): 
3500, 2965, 1811, 1750, 1685, 1348, 1237, 1171, 1026; 1H-NMR (500 MHz, CDCl3, δ / ppm): 
6.04 (1H, d, J = 10.5 Hz, H-10), 5.63 (1H, d, J = 10.5 Hz, H-9), 4.88 (1H, d, J = 4.5 Hz, H-2), 
4.57–4.55 (1H, m, H-5), 3.78 (1H, d, J = 19.5 Hz, H-14), 2.98 (3H, s, Ms), 2.85 (1H, d, J = 
= 19.0 Hz, H-14), 2.79 (1H, d, J = 4.5 Hz, H-3), 2.27 (3H, s, H-18), 2.11 (3H, s, Ac), 2.05 
(3H, s, Ac), 2.05–2.00 (1H, m, H-6), 1.92–1.85 (1H, m, H-6), 1.76–1.69 (3H, m, 2×H-7), 1.68 
(3H, s, H-16 or H-17), 1.57 (3H, s, H-20), 1.34 (3H, s, H-16 or H-17), 1.03 (3H, s, H-19); 13C-
-NMR (125 MHz, CDCl3, δ / ppm): 197.00 (C, C-13), 170.28 (C, Ac), 169.21 (C, Ac), 152.42 
(C, CO), 149.52 (C, C-11), 143.40 (C, C-12), 89.21 (C, C-1), 84.93 (CH, C-5), 80.23 (CH, C-
2), 75.43 (CH, C-9), 73.38 (C, C-4), 72.68 (CH, C-10), 44.11 (CH, C-3), 43.57 (C, C-8), 
41.33 (C, C-15), 40.89 (CH2, C-14), 38.69 (CH3, Ms), 32.82 (CH3, C-16 or C-17), 26.42 (CH3, 
C-20), 25.46 (CH2, C-6), 25.25 (CH2, C-7), 20.72 (CH3, Ac), 20.64 (CH3, Ac), 20.08 (CH3, 
C-16 or C-17), 18.57 (CH3, C-19), 13.83 (CH3, C-18). HRMS (ESI-TOF high acc) calcd. for 
C26H37O12S (MH+): 573.2000, found: 573.1992. 
Compound 9. A mixture of sodium iodide (12.5 mg, 0.084 mmol) and MOMCl (8.4 mg, 
0.104 mmol) in DME (0.2 mL) was stirred for 10 min at rt. Then a solution of 3 (6.4 mg, 
0.010 mmol) and DIPEA (14.8 mg, 0.114 mmol) in DME (0.5 mL) was stirred for 20 min at rt 
and overnight under reflux. A second portion of sodium iodide (25 mg,), MOMCl (17 mg) and 
DIPEA (30 mg) were added and stirring of the reaction mixture was continued for additional 
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24 h. The reaction mixture was quenched with saturated NaHCO3 and water and extracted 
twice with methylene chloride. The combined extracts were washed with brine, dried over 
MgSO4 and concentrated under reduced pressure. The residue was purified by column chro-
matography (eluent: benzene/ethyl acetate = 6/4) to give compound 9 (1.4 mg, 26%) as a 
colorless film. 1H-NMR (200 MHz; CDCl3, δ / ppm): 6.02 (1H, d, J = 10.4 Hz), 5.89–5.66 
(2H, m), 5.70 (1H, d, J = 10.0 Hz), 5.60–5.52 (1H, m), 5.12–4.97 (2H, m), 4.92 (1H, d, J = 6.6 
Hz), 3.75 (1H, d, J = 19.1 Hz), 2.83 (1H, d, J = 19.5 Hz), 2.40–1.92 (6H, m), 2.33 (1H, d, J = 
= 6.3 Hz), 2.10 (3H, s), 2.08 (3H, s), 2.06 (3H, s), 1.67 (3H, s), 1.31 (3H, s), 1.03 (3H, s).  
Compound 10. To a solution of 3 (150 mg, 0.245 mmol) and imidazole (166 mg, 2.45 
mmol, 10 eq) in DMF (1.2 mL) was added chlorodimethylsilane (231 mg, 2.45 mmol, 10 eq) 
dropwise at 0 °C, under an argon atmosphere. The reaction mixture was stirred at 0 °C for 15 
min, and then at 55 °C for 1 h. After this period of time, imidazole (166 mg) and chlorodi-
methylsilane (231 mg) were added and the reaction was stirred at 55 °C for another hour. The 
reaction mixture was diluted with CH2Cl2, washed with water, dried over anhydrous MgSO4 
and concentrated under reduced pressure. Purification by dry-flash chromatography (eluent: 
benzene/ethyl acetate = 7/3) gave compound 10 (110 mg, 67 %) as a colorless film. IR (film, 
cm-1): 2964, 1811, 1750, 1685, 1342, 1233, 1173, 1027; 1H-NMR (500 MHz, CDCl3, δ / ppm): 
6.02 (1H, d, J = 10.0 Hz, H-10), 5.77–5.69 (1H, m, H-22), 5.62 (1H, d, J = 10.0 Hz, H-9), 5.05 
(1H, broad dd, J = 1.5 and 17.0 Hz, H-23), 5.02 (1H, dd, J = 1.0 and 10.5 Hz, H-23), 4.87– 
–4.85 (2H, m, H-5 and Si-H), 4.82 (1H, d, J = 4.5 Hz, H-2), 3.75 (1H, d, J = 19.0 Hz, H-14), 
3.02 (3H, s, Ms), 2.80 (1H, d, J = 19.0 Hz, H-14), 2.72 (1H, d, J = 4.5 Hz, H-3), 2.29–2.24 
(2H, m, H-21 and H-20), 2.29 (3H, s, H-18), 2.22–2.10 (2H, m, H-6 and H-21), 2.10 (3H, s, 
Ac), 2.05 (3H, s, Ac), 2.03–1.99 (1H, m, H-20), 1.78–1.73 (3H, m, H-6 and 2×H-7), 1.66 (3H, 
s, H-16 or H-17), 1.33 (3H, s, H-16 or H-17), 1.09 (3H, s, H-19), 0.32 (3H, d, J = 3.0 Hz, 
Si-CH3), 0.29 (3H, d, J = 2.5 Hz, Si-CH3); 13C-NMR (125 MHz, CDCl3, δ / ppm): 196.99 (C, 
C-13), 170.44 (C, Ac), 169.42 (C, Ac), 152.78 (C, CO), 150.63 (C, C-11), 142.90 (C, C-12), 
136.91 (CH, C-22), 116.03 (CH2, C-23), 88.83 (C, C-1), 81.13 (CH, C-5), 79.89 (C, C-4), 
79.78 (CH, C-2), 75.92 (CH, C-9), 73.20 (CH, C-10), 45.53 (CH, C-3), 44.75 (C, C-8), 41.50 
(C, C-15), 41.29 (CH2, C-14), 39.99 (CH3, Ms), 35.69 (CH2, C-20), 33.20 (CH3, C-16 or 
C-17), 28.76 (CH2, C-21), 25.37 (CH2, C-7), 25.16 (CH2, C-6), 20.94 (CH3, Ac), 20.86 (CH3, 
Ac), 20.27 (CH3, C-16 or C-17), 19.64 (CH3, C-19), 13.80 (CH3, C-18) 1.04 (CH3, DMS), 
0.95 (CH3, DMS). HRMS (ESI-TOF high acc) calcd. for C31H47O12SSi (MH+): 671.2552, 
found: 671.2530. 
Compound 11. OsO4 (30 μL of a 2.5% solution in t-BuOH) was added to a solution of 10 
(9.6 mg, 0.015 mmol) in a mixture of THF (0.6 mL) and water (0.3 mL), followed by the 
addition of NaIO4 (16 mg, 0.075 mmol; 5 eq). The reaction mixture was stirred for 1 h at rt, 
then sodium dithionite (50 mg) was added and stirring was continued for 20 min. The reaction 
mixture was diluted with CH2Cl2, washed with aq. Na2S2O3 and water, dried over anhydrous 
MgSO4 and concentrated under reduced pressure. The crude product was roughly purified by 
dry-flash chromatography (eluent: petrol ether/ethyl acetate = 1/1) affording 11 (4.3 mg; 42 %) 
as a colorless film. 1H-NMR (200 MHz, CDCl3, δ / ppm): 9.81 (1H, s), 6.00 (1H, d, J = 10.0 
Hz), 5.63 (1H, d, J = 10.0 Hz), 4.83 (1H, d, J = 5.0 Hz), 4.82 (1H, bs), 3.73 (1H, d, J = 19.2 
Hz), 3.10 (3H, s, Ms), 2.84 (1H, d, J = 19.2 Hz), 2.99–2.67 (2H, m), 2.66 (1H, d, J = 4.6 Hz), 
2.49–2.35 (1H, m), 2.26 (3H, s, H-18), 2.25–2.11 (2H, m), 2.11 (3H, s, Ac), 2.06 (3H, s, Ac), 
1.90–1.66 (3H, m), 1.68 (3H, s), 1.35 (3H, s), 1.13 (3H, s), 0.26 (3H, s), 0.23 (3H, s). 
Compound 12. Into a cold (–80 °C) solution of 10 (45 mg, 0.067 mmol) in CH2Cl2 was 
bubbled ozone gas until the solution became light blue. Excess ozone was purged from the 
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reaction by bubbling argon through the cold reaction mixture for 10 min, followed by the 
addition of dimethyl sulfide (0.2 mL). The reaction mixture was stirred at room temperature 
overnight and  concentrated under reduced pressure. Purification of the residue by column 
chromatography (eluent: benzene/ethyl acetate = 7/3) gave compound 12 (27 mg, 58 %) as a 
colorless film. IR (film, cm-1): 2965, 1810, 1750, 1685, 1341, 1233, 1174, 1031; 1H-NMR 
(500 MHz, CDCl3, δ / ppm): 9.80 (1H, s, CHO), 6.01 (1H, d, J = 10.5 Hz, H-10), 5.63 (1H, d, 
J = 10.0 Hz, H-9), 4.87 (1H, d, J = 4.5 Hz, H-2), 4.82 (1H, m, Si-H), 4.73 (1H, bd, J = 2.5 Hz, 
H-5), 3.67 (1H, d, J = 19.0 Hz, H-14), 3.04 (3H, s, Ms), 2.82 (1H, d, J = 19.0 Hz, H-14), 
2.80–2.75 (2H, m, 2×H-21), 2.75 (1H, d, J = 5.0 Hz, H-3), 2.46–2.39 (1H, m, H-20), 2.29 (3H, 
s, H-18), 2.25–2.22 (2H, m, H-6 and H-20), 2.11 (3H, s, Ac), 2.05 (3H, s, Ac), 1.90–1.83 (1H, 
m, H-6), 1.76–1.74 (2H, m, 2×H-7), 1.67 (3H, s, H-16 or H-17), 1.33 (3H, s, H-16 or H-17), 
1.10 (3H, s, H-19), 0.31 (3H, d, J = 3.0 Hz, Si-CH3), 0.30 (3H, d, J = 3.5 Hz, Si-CH3). 13C- 
-NMR (125 MHz, CDCl3, δ / ppm): 199.99 (C, CHO), 196.54 (C, C-13), 170.15 (C, Ac), 
169.17 (C, Ac), 152.29 (C, CO), 150.44 (C, C-11), 142.53 (C, C-12), 88.66 (C, C-1), 81.14 
(CH, C-5), 79.45 (C, C-4), 79.19 (CH, C-2), 75.56 (CH, C-9), 72.88 (CH, C-10), 45.30 (CH, 
C-3), 44.39 (C, C-8), 41.20 (C, C-15), 40.99 (CH2, C-14), 39.81 (CH3, Ms), 39.75 (CH2, C-21), 
32.93 (CH3, C-16 or C-17), 28.46 (CH2, C-20), 25.24 (CH2, C-7), 24.77 (CH2, C-6), 20.65 
(CH3, Ac), 20.56 (CH3, Ac), 19.99 (CH3, C-16 or C-17), 19.05 (CH3, C-19), 13.53 (CH3, C-18), 
0.83 (CH3, DMS), 0.65 (CH3, DMS). HRMS (ESI-TOF high acc) calcd. for C30H45O13SSi 
(MH+): 673.2345, found: 673.2335. 
Compound 13. To a solution of 12 (22 mg, 0.032 mmol) in DMF (0.6 mL) oxone (60 mg, 
0.098 mmol, 3 eq) was added in one portion and the reaction was stirred at rt for 2 h. The 
reaction mixture was diluted with ethyl acetate, washed with water, dried over anhydrous 
MgSO4 and concentrated under reduced pressure. The residue was dissolved in THF at 0 °C 
and ethereal solution of diazomethane was slowly added. The reaction mixture was stirred at 0 
°C for 1 h and concentrated under reduced pressure. Purification by column chromatography 
(eluent: benzene/ethyl acetate = 7/3) gave compound 13 (14 mg, 61%) as a colorless film. IR 
(film, cm-1): 2959, 1809, 1743, 1682, 1373, 1339, 1234, 1174, 1024; 1H-NMR (500 MHz, 
CDCl3, δ / ppm): 6.01 (1H, d, J = 10.0 Hz, H-10), 5.63 (1H, d, J = 10.0 Hz, H-9), 4.85–4.82 
(2H, m, H-2 and Si-H), 4.76 (1H, bd, J = 2.0 Hz, H-5), 3.70 (3H, s, CO2Me), 3.68 (1H, d, J = 
= 19.0 Hz, H-14), 3.04 (3H, s, Ms), 2.82 (1H, d, J = 19.5 Hz, H-14), 2.74 (1H, d, J = 4.5 Hz, 
H-3), 2.57–2.52 (2H, m, 2×H-21), 2.49–2.44 (1H, m, H-20), 2.29 (3H, s, H-18), 2.29–2.24 
(2H, m, H-6 and H-20), 2.11 (3H, s, Ac), 2.06 (3H, s, Ac), 1.92–1.85 (1H, m, H-6), 1.76–1.72 
(2H, m, 2×H-7), 1.67 (3H, s, H-16 or H-17), 1.33 (3H, s, H-16 or H-17), 1.12 (3H, s, H-19), 
0.33 (3H, d, J = 2.5 Hz, Si-CH3), 0.30 (3H, d, J = 2.5 Hz, Si-CH3); 13C-NMR (125 MHz, 
CDCl3, δ / ppm): 196.66 (C, C-13), 172.93 (C, CO2Me), 170.21 (C, Ac), 169.25 (C, Ac), 
152.37 (C, CO), 150.49 (C, C-11), 142.62 (C, C-12), 88.65 (C, C-1), 80.99 (CH, C-5), 79.48 
(C, C-4), 79.26 (CH, C-2), 75.60 (CH, C-9), 72.94 (CH, C-10), 52.01 (CH3, CO2Me), 45.33 
(CH, C-3), 44.43 (C, C-8), 41.23 (C, C-15), 41.01 (CH2, C-14), 39.87 (CH3, Ms), 33.00 (CH3, 
C-16 or C-17), 31.82 (CH2, C-20), 29.83 (CH2, C-21), 25.27 (CH2, C-7), 24.83 (CH2, C-6), 
20.74 (CH3, Ac), 20.65 (CH3, Ac), 20.05 (CH3, C-16 or C-17), 19.19 (CH3, C-19), 13.59 
(CH3, C-18) 0.82 (CH3, DMS), 0.66 (CH3, DMS). HRMS (ESI-TOF high acc) calcd. for 
C31H46O14SSiNa (MNa+): 725.2270, found: 725.2259. 
Compound 14. OsO4 (20 μL of a 2.5% solution in t-BuOH) was added to a solution of 3 
(7 mg, 0.0011 mmol) in a mixture of THF (0.6 mL) and water (0.3 mL), followed by the 
addition of NaIO4 (12.1 mg, 0.057 mmol; 5 eq). The reaction mixture was stirred for 1 h at rt, 
then sodium dithionite (40 mg) was added and stirring was continued for 20 min. The reaction 
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mixture was diluted with CH2Cl2, washed with aq. Na2S2O3 and water, dried over anhydrous 
MgSO4 and concentrated under reduced pressure. The crude product was roughly purified by 
dry-flash chromatography (eluent: petrol ether/ethyl acetate = 1/1) affording hemiacetal (3.7 
mg) that was used in the next step. Jones reagent (25 μL, 0.009 mmol; 1.5 eq) was added to a 
solution of hemiacetal (3.7 mg, 0.006 mmol) in acetone (0.5 mL) at 0 °C, and the resulting 
mixture was stirred for 15 min, when isopropanol (100 μL) was added. The reaction mixture 
was diluted with CH2Cl2, washed with brine, dried over anhydrous MgSO4 and concentrated 
under reduced pressure. Purification by coloumn chromatography (eluent: benzene/ethyl 
acetate = 1/2) gave compound 14 (3.5 mg, 49% over two steps) as a colorless film. IR (film, 
cm-1): 2993, 2937, 1816, 1746, 1685, 1370, 1353, 1233, 1174, 1024; 1H NMR (500 MHz, 
CDCl3, δ / ppm): 6.06 (1H, d, J = 10.5 Hz, H-10), 5.67 (1H, d, J = 10.0 Hz, H-9), 4.85 (1H, 
bd, J = 5.0 Hz, H-2), 4.67 (1H, bt, J = 2.5 Hz, H-5), 3.54 (1H, d, J = 19.5 Hz, H-14), 3.06 (1H, 
d, J = 5.0 Hz, H-3), 3.01 (3H, s, Ms), 2.94 (1H, dd, J = 19.5 Hz, H-14), 2.82–2.74 (1H, m, 
H-21), 2.67–2.58 (2H, m, H-20 and H-21), 2.27 (3H, s, H-18), 2.14–2.10 (1H, m, H-6), 2.12 
(3H, s, Ac), 2.06 (3H, s, Ac), 1.97–1.91 (2H, m, H-6 and H-20), 1.81 (1H, ddd, J = 2.5, 4.0 
and 14.0 Hz, H-7), 1.74 (1H, dd, J = 3.5 and 13.5 Hz, H-7), 1.68 (3H, s, H-16 or H-17), 1.35 
(3H, s, H-16 or H-17), 1.003 (3H, s, H-19); 13C-NMR (125 MHz, CDCl3, δ / ppm): 196.44 (C, 
C-13), 173.12 (C, C-22), 170.07 (C, Ac), 169.17 (C, Ac), 151.45 (C, CO), 149.82 (C, C-11), 
143.32 (C, C-12), 88.65 (C, C-1 or C-4), 85.16 (C, C-1 or C-4), 81.66 (CH, C-5), 78.63 (CH, 
C-2), 74.59 (CH, C-9), 72.49 (CH, C-10), 43.89 (C, C-8), 41.60 (C, C-15), 41.51 (CH, C-3), 
40.53 (CH2, C-14), 39.10 (CH3, Ms), 32.79 (CH3, C-16 or C-17), 28.99 (CH2, C-20), 27.41 
(CH2, C-21), 24.84 (2×CH2, C-6 and C-7), 20.71 (CH3, Ac), 20.58 (CH3, Ac), 20.07 (CH3, 
C-16 or C-17), 18.38 (CH3, C-19), 13.86 (CH3, C-18). HRMS (ESI-TOF high acc) calcd. for 
C28H37O13S (MH+): 613.1949, found: 613.1922. 
CONCLUSIONS 
In conclusion, triol 4, a versatile starting compound in the synthesis of seve-
ral taxane analogues, was converted into ester 13 – an advanced intermediate in 
the attempted synthesis of cyclobutane taxane analogue 1. However, the cycliza-
tion failed, due to the unexpected instability of the DMS protecting group in 13 
under basic conditions. In addition, useful information was acquired on the reac-
tivity of the obtained taxoid intermediates, as well as on the dimethylsilane (DMS) 
protecting group. Observation that alcohol 3 has the propensity for elimination of 
C5 mesylate and the formation of the Δ5,6 double bond provides a possibility for 
a future investigation of 5,6-dehydro-C,D-spirolactone analogues. The synthesis 
and biological evaluation of a novel taxane analogue with a C,D-spirolactone 
moiety would be of considerable interest, bearing in mind the fact that this type 
of taxoids show mechanistically different cytotoxic action as compared to pacli-
taxel. 
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И З В О Д  
СИНТЕТИЧКЕ СТУДИЈЕ АНАЛОГА ПАКЛИТАКСЕЛА СА 
МОДИФИКОВАНИМ D-ПРСТЕНОМ 
ЗОРАНА ФЕРЈАНЧИЋ1, РАДОМИР МАТОВИЋ2 и РАДОМИР Н. САИЧИЋ1 
1Хемијски факултет Универзитета у Београду, Студентски трг 12–16, п. пр. 158, 11000 Београд и 
2ИХТМ – Центар за хемију, Његошева 12, 11000 Београд 
Развијена је синтетичка секвенца за добијање 9,10-ди-О-ацетил-4-десметилен-4β- 
-(3-бутенил)-4α-хидрокси-5-О-мезилтаксицин I-1,2-карбоната (3), интермедијера у по-
кушаној синтези циклобутанског аналога паклитаксела. Испитивана је могућност даље 
хемијске трансформације једињења 3, као што је заштита стерно изразито заштићене 
C-4α хидроксилне групе и оксидативна фрагментација терминалне двоструке везе. Ци-
клизација једињења 13 није дала жељени резултат – интермедијер са циклобутановим 
прстеном, што је последица неочекиване нестабилности DМS-заштитне групе у базним 
реакционим условима. 
(Примљено 26. јуна 2012) 
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